DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Schachter J, Ribas A, Long GV. et al.
Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Lancet (London, England) 2017;
390: 1853-1862
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.